In 2015, the second human pegivirus (HPgV-2) was independently reported by 2 groups in the United States ([@R1],[@R2]). Previous reports have indicated that HPgV-2 (also known as HHpgV-1) is a transfusion-transmitted virus and is associated with hepatitis C virus (HCV) infection ([@R1]--[@R5]). The distribution and prevalence of HPgV-2 infection worldwide are of great importance but remain to be determined. In this study, we demonstrate the existence of HPgV-2 in the southern province of Guangdong and southwestern province of Sichuan in China. We have also identified HCV-infected persons, in particular HCV/HIV-1 co-infected persons who inject drugs (PWID), as populations at high risk for HPgV-2 infection. In addition, our work reveals the difference in the prevalence, distribution, and phylogeny between the first human pegivirus (HPgV; formerly GB virus C or hepatitis G virus) ([@R6],[@R7]) and HPgV-2.

The Study
=========

In our initial investigation of HPgV-2, we screened a total of 367 delinked serum or plasma samples from high-risk groups for infection with HCV and HIV-1 and 500 healthy volunteer blood donors from Guangdong Province, China, by using ELISA ([@R2],[@R5]), and a nested reverse transcription PCR targeting both the 5′ untranslated region and nonstructural protein 3 regions of HPgV-2 ([@R3],[@R5]). We observed a low frequency (0.4%) of HPgV-2 antibody detection and the absence of HPgV-2 viremia in healthy blood donors tested in our study. Out of 86 HCV-infected patients, 1 (1.2%) was positive for both HPgV-2 antibodies and viral RNA ([Table 1](#T1){ref-type="table"}). Furthermore, we did not detect HPgV-2 RNA in men who have sex with men (MSM), although 1 (0.5%) of the 211 MSM was weakly positive for HPgV-2 antibodies and negative for HPgV-2 RNA ([Table 1](#T1){ref-type="table"}; [Figure 1](#F1){ref-type="fig"}).

###### Detection frequencies of HPgV-2 in different populations in Guangdong and Sichuan Provinces, China\*

  Province, group, and subgroup   No. tested   HPgV-2     HPgV RNA+, no. (%)   
  ------------------------------- ------------ ---------- -------------------- -----------
  Ab--/RNA+                       7            0          0                    0
  Ab+/RNA--                       22           0          0                    4 (18.2)
  Total                           86           1 (1.2)    1 (1.2)              12 (14.0)
  PWID                                                                         
  HIV-1+/HCV Ab+/RNA+             70           9 (12.9)   4 (5.7)              28 (40.0)
  MSM                                                                          
  HIV-1+/HCV+                     12           1 (8.3)    0                    4 (33.3)
  HIV-1+/HCV--                    100          0          0                    28 (28.0)
  HIV-1--/HCV+                    10           0          0                    1 (10.0)
  HIV-1--/HCV--                   89           0          0                    7 (7.9)
  Total                           211          1 (0.5)    0                    40 (19.0)
  Blood donors                                                                 
  HIV-1--/HCV--/HBV--             500          2 (0.4)    0                    NT
  HCV Ab+/HCV RNA+                2            2          2                    NT

  Sichuan Province                               
  ------------------ ----- ----------- --------- ----
  PWID                                           
  HIV-1+/HCV Ab+     270   43 (15.9)   8 (3.0)   NT

\*Ab, antibodies; HBV, hepatitis B virus; HCV, hepatitis C virus; HPgV, human pegivirus; HPgV-2, second human pegivirus; MSM, men who have sex with men; NT, not tested; PWID, people who inject drugs; +, positive; --, negative.

![Detection of second human pegivirus (HPgV-2) antibodies in different samples in Guangdong and Sichuan Provinces, China. Serum or plasma samples from 86 HCV-infected patients, 70 PWID, 122 MSM, and 102 blood donors (100 samples that were negative for HPgV-2 antibodies plus 2 positive samples) are included. The antibody titers from each sample are plotted on the *y*-axis. HPgV-2 RNA--positive samples are shown in red. HCV, hepatitis C virus; MSM, men who have sex with men; OD~450~, optical density at 450 nm; PWID, persons who inject drugs.](16-1162-F1){#F1}

We observed a relatively high prevalence of HPgV-2 infection in HCV/HIV-1 co-infected PWID in Guangdong Province; 12.9% (9/70) were positive for HPgV-2 antibodies and 5.7% (4/70) for HPgV-2 RNA ([Table 1](#T1){ref-type="table"}). We obtained similar results from 270 PWID from Sichuan Province; 15.9% (43/270) were positive for HPgV-2 antibodies and 3.0% (8/270) for HPgV-2 RNA ([Table 1](#T1){ref-type="table"}). Using the Fisher exact test, we observed a statistically significant difference between HCV-positive and HCV-negative patients in the prevalence of having HPgV-2 antibodies (6.2% vs. 0; p\<0.001) and prevalence of having HPgV-2 RNA (5% vs. 0; p = 0.026). Similarly, we observed a statistically significant difference between HIV-1--positive/HCV-positive patients and HIV-1--positive/HCV-negative patients in the prevalence of having HPgV-2 antibodies (10% vs. 0; p\<0.001) and prevalence of having HPgV-2 RNA (4% vs. 0; p = 0.040) ([Table 2](#T2){ref-type="table"}). These findings indicate a close association between HPgV-2 and HCV infection and synergy between HIV-1 and HCV infection with respect to HPgV-2 infections ([@R5]).

###### Comparison of HPgV and HPgV-2 infections among HCV-, HIV-1--, and HIV-1/HCV--infected populations in Guangdong Province, China\*

  Group       No. tested   HPgV-2 Ab+             HPgV-2 RNA+             HPgV RNA+                  
  ----------- ------------ ------------ --------- ------------- --------- ----------- -- ----------- ---------
  HCV                                                                                                
  \+          178          11 (6.2)     \<0.001                 5 (2.8)   0.026          45 (25.3)   0.130
  --          189          0 (0)                  0 (0)                   35 (18.5)                  
  HIV-1                                                                                              
  \+          182          10 (5.5)     0.005                   4 (2.2)   0.212          60 (33.0)   \<0.001
  --          185          1 (0.5)                1 (0.5)                 20 (10.8)                  
  HIV-1/HCV                                                                                          
  +/+         82           10 (12.2)    \<0.001                 4 (4.9)   0.040          32 (39.0)   0.154
  +/−         100          0 (0)                  0 (0)                   28 (28.0)                  

\*p values calculated by using Fisher exact test. Ab, antibodies; HCV, hepatitis C virus; HPgV, human pegivirus; HPgV-2, second human pegivirus; +, positive; --, negative.

Furthermore, we obtained 6 near full-length genome sequences of HPgV-2 by using next-generation sequencing or sequencing of PCR products ([@R5]). These strains from China, which included 2 from PWID (IDU31 and SC-LS-01), 2 from HCV-infected patients (HCV-121 and C346), and 2 from HCV-infected blood donors (HCV1241 and HCV1563), exhibited an identity of 93.6%--97.8% at the whole-genome level. Compared with other HPgV-2 strains from the United States and United Kingdom, the nucleotide sequence identity was 93.7%--96.2%. Sequence divergence was greatest at synonymous sites, with ratios of nonsynonymous to synonymous nucleotide substitutions of 0.125--0.150, which are consistent with other reports ([@R1]--[@R3]). Phylogenetic analysis indicated that HPgV-2 strains from China, the United States, and the United Kingdom clustered together to form a separate branch and fell into group 1 with the closely related pegiviruses from bats and rodents ([Figure 2](#F2){ref-type="fig"}). Other pegiviruses from human, simian, and equine sources formed group 2, in which the variants of HPgV fell into a separate clade. These results illustrate the difference between the 2 human pegiviruses ([@R1],[@R2],[@R8]) and the low level of genetic diversity of HPgV-2 strains ([@R1]--[@R3]).

![Phylogenetic analysis of second human pegivirus (HPgV-2) isolates identified in our study (China) and abroad (UK and US). Phylogenetic trees of nucleotide sequences from complete sequences of HPgV-2 strains isolated in our study and elsewhere as well as hepatitis C virus and pegivirus strains from humans, simians, equids, bats, and rodents are included. The phylogenetic trees were constructed with the neighbor-joining tree method using MEGA6 software (<http://www.megasoftware.net>). Bootstrap analysis with 1,000 replicates was performed to determine the robustness of branching; values are shown on branches. Scale bar indicates the estimated number of nucleotide substitutions per site. The near full-length genome sequences of HPgV-2 identified in this study have been submitted to GenBank under accession numbers KX528230 (HCV-121), KX528231 (IDU31), KY971606 (C346), MG457178 (SC-LS-01), MF770985 (HCV1241), and MF770986 (HCV1563). UK, United Kingdom; US, United States.](16-1162-F2){#F2}

In contrast to our findings on HPgV-2 infection, we observed a high frequency of HPgV infection across all 3 populations tested (HCV-infected patients, PWID, and MSM) ([Tables 1](#T1){ref-type="table"}, [2](#T2){ref-type="table"}). The percentage of HPgV viremia was 14.0% (14/86) in HCV-infected patients, 19.0% (40/211) in MSM, and 40.0% (28/70) in PWID ([Table 1](#T1){ref-type="table"}). Among MSM, the prevalence of HPgV RNA was 28.0% (28/100) in those who were infected with HIV-1 alone and 33.3% (4/12) in those who were HIV-1/HCV co-infected ([Table 1](#T1){ref-type="table"}). For MSM who were negative for both HIV-1 and HCV, 7.9% (7/89) were positive for HPgV RNA ([Table 1](#T1){ref-type="table"}).

Conclusions
===========

We report the detection of the second human pegivirus, HPgV-2, in HCV-infected (in particular HCV/HIV-1 co-infected) persons in Guangdong and Sichuan Provinces, China ([Table 1](#T1){ref-type="table"}). Our results and those from previous studies demonstrate that the virus occurs in several geographically distinct regions in the world ([@R1]--[@R4],[@R9],[@R10]).

HPgV and HPgV-2 are the only known human pegiviruses ([@R8]), and comparing their association with HCV and HIV-1 infection is of great interest. Consistent with previous reports, we found that the prevalence of HPgV viremia was 7.9% in HCV and HIV-1--negative MSM and 33.3%--40% in HCV/HIV-1 co-infected MSM and PWID ([Table 1](#T1){ref-type="table"}). In contrast, only 0.5% of MSM and 0.4% of healthy blood donors were positive for HPgV-2 antibodies, but all were negative for HPgV-2 RNA ([Table 1](#T1){ref-type="table"}). These results indicate that HPgV-2 infection might be much less frequent than HPgV infection, possibly because of its low transmissibility or high clearance rate ([@R2]--[@R4]). The dramatic difference of distribution and prevalence between HPgV and HPgV-2 infections in different populations provides a clue for investigation of disease association with HPgV-2. HPgV does not cause human diseases ([@R11]) and can inhibit HIV-1 replication as well as prolong survival of HIV-1--infected and Ebola virus--infected patients ([@R12]--[@R14]). However, possible pathogenicity and disease association of HPgV-2 remain to be elucidated.

The high-risk populations susceptible to HPgV-2 infection include HCV-infected patients and, in particular, HCV/HIV-1 co-infected PWID. Most (93.3%) of HPgV-2 infected patients were also co-infected with HCV ([@R1]--[@R4]). Notably, the relatively high frequency of HPgV-2 RNA detection was observed in HCV/HIV-1 co-infected PWID in Guangdong (5.7%) and Sichuan (3.0%) Provinces of China ([Table 1](#T1){ref-type="table"}) and in the United States (10.9%) ([@R9]). In contrast, a somewhat lower percentage (1.7%) of HCV-positive PWID in the United Kingdom were reported to be HPgV-2 RNA positive, whereas none of the 30 HIV-1 singly infected and 36 HCV/HIV-1 co-infected PWID were positive for HPgV-2 RNA ([@R3]). These discordant results warrant more studies in different countries to address the association between HPgV-2 and HCV/HIV-1 co-infection.

Our findings are subject to 2 limitations. First, because a limited number of samples from only 2 provinces of China were tested, the results might not represent overall prevalence of HPgV-2 infection throughout all of China. Second, this study was a cross-sectional rather than a longitudinal study, therefore, the proportions of persistent infection and natural history of HPgV-2 infection remain to be determined.

Future studies should address several questions: whether the close association between HPgV-2 and HCV infection represents a biologic dependence of these 2 viruses; how HCV/HIV-1 co-infection facilitates HPgV-2 infection; and whether HCV or HIV-1 viral proteins enhance the transmissibility or infectivity of HPgV-2. In addition, because the rarity of HPgV-2 detection in MSM could be a result of the low frequency of HCV or HIV-1 infection or the transmission route of HPgV-2, further research should aim to determine if HPgV-2 is more like a transfusion-transmitted virus rather than a sexually transmitted virus.
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